SFSandrine Chan Moi Fat

Sandrine Chan Moi Fat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandrine Chan Moi Fat has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Dominic Brock Rowe

    MND Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia

    6 shared publications
  • Kelly Louise Williams

    Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia

    6 shared publications
  • Lyndal Henden

    Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia

    5 shared publications
  • Ian P. Blair

    Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia

    4 shared publications
  • Natalie Grima

    Macquarie University Brain Institute and Clinic, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia

    4 shared publications
  • Emily P. McCann

    Macquarie University Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia

    3 shared publications

Latest Publications

  • Open Access

    Motor neuron disease in rural Australia: a population-based observational study of epidemiology, clinical characteristics and regional variation

    by Amanda L. Wright, Zoe N. Zussa, Sandrine Chan Moi Fat, Carol M. Y. Lee, Louis Christie, Catherine Keniry, Simon Hawke, Dominic B. Rowe, Kelly L. Williams, Lyndal Henden

    Objectives: To characterise the epidemiology, clinical features, and geographic distribution of motor neuron disease (MND) within a rural Australian population. Design: Retrospective, population-based epidemiology study. Setting: Western New South Wales Local Health District (WNSWLHD), Australia, from 1 January 2023 to 31 December 2025. Participants: Fifty-one individuals diagnosed with MND identified through Central West Neurology and Neurosurgery, Orange Palliative Care Service, and the WNSWLHD Neurodegenerative Community Care Team. Main outcome measures: Crude and age-standardised incidence, prevalence and mortality rates of MND; demographic and clinical characteristics; geographic distribution of prevalence. Results: The all-age crude incidence of MND was 4.01 per 100,000 person-years (95% CI, 2.78-5.60), prevalence was 8.14 per 100,000 population (95% CI, 6.33-10.30), and mortality was 3.77 per 100,000 person-years (95% CI, 2.58-5.33). Females comprised 51% of patients and showed higher incidence, prevalence and mortality than males. Bulbar-onset MND accounted for 47% of patients, including 61% of females. MND prevalence varied across the health district, with the highest burden observed in central and south-eastern regional areas. Patients travelled on average 139 km to access neurological care, with a diagnostic delay of nine months. Conclusions: MND incidence and mortality are high in this rural Australian population compared with national and global estimates, with an overrepresentation of bulbar-onset disease and altered sex distribution. These findings provide an important baseline for population-level MND surveillance, following the introduction of mandatory notification in NSW, Australia. Findings also highlight the need for strengthened rural healthcare services, and further research of potential genetic and environmental contributors to MND risk.

  • Open Access

    Motor Neuron Disease Mortality Trends in Australia From 1986 to 2023: A Population‐Based Study

    by Carol M. Y. Lee, Rupendra N. Shrestha, Julian Gold, Mark Stevenson, Kelly L. Williams, Lyndal Henden, Sandrine K. K. Chan Moi Fat, Zoe Zussa, Amanda Wright, Martin Jude, et al.

    Objectives: To analyse longitudinal change in motor neuron disease (MND) mortality in Australia from 1986 to 2023. Design: Australian population‐based study of MND mortality. Setting: All MND mortality and Australian population data from 1 January 1986 to 31 December 2023 were obtained from the Australian Bureau of Statistics. Main Outcome Measures: MND mortality records were analysed, and certified deaths were summarised by year of registration. MND mortality rates, 95% confidence intervals (CIs) and Joinpoint regression trends were calculated. Data were further subset by demographic and geographical categories to report Australian MND mortality by age group, sex, state/territory location and remoteness areas classification. Results: In Australia, the total number of MND deaths more than tripled over the past 37 years, from 238 in 1986 to 781 in 2023. The unadjusted mortality rate in 1986 was 1.49 (95% CI , 1.30–1.69) per 100,000 population and increased to 2.93 (95% CI , 2.73–3.14) per 100,000 population by 2023. After age standardisation, the annual percentage change across 1986–2023 was determined to be 0.47% (95% confidence limit, 0.16–0.86). Joinpoint modelling suggests a more recent reduction in adjusted mortality rates. In 2023, MND accounted for 0.43% of all‐cause deaths in Australia, increasing from 0.21% in 1986. The number of MND deaths in Australia peaked at age 70–79 years. MND mortality was higher among men than women (rate ratio, 1.41; 95% CI , 1.33–1.51). MND mortality rates were similar among New South Wales, Victoria and Queensland (2.93, 3.08 and 2.85 per 100,000 population, respectively), with higher rates in South Australia and Tasmania (3.44 and 4.12 per 100,000 population, respectively). MND mortality rates were higher in inner and outer regional areas (3.90 and 3.24 per 100,000 population, respectively) compared with major cities (2.79 per 100,000 population). Conclusions: Adjusted MND mortality rates in Australia increased over 37 years.


  • Open Access

    Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis

    by Zoe N. Zussa, Andrew N. Smith, Joke J.F.A van Vugt, Daniel S. O’SHaughnessy, Natalie Grima, Sandrine Chan Moi Fat, Ian P. Blair, Dominic B Rowe, Roger Pamphlett, Garth A Nicolson, et al.

    Background and objectives: A pathogenic GGC repeat expansion in the zinc finger homeobox 3 ( ZFHX3 ) gene, encoding a pure polyglycine tract, is the cause of spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci contribute to the risk of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease involving the progressive loss of motor neurons. There is increasing awareness of the role of short tandem repeat (STR) motif composition and configuration in disease pathogenicity. Given the genetic pleiotropy between ALS and SCA, this study aimed to evaluate whether ZFHX3 GGC expansions were associated with ALS and to characterise repeat motif composition. Methods: ExpansionHunter v5 was used to genotype ZFHX3 GGC repeat sizes in short-read whole genome sequencing data from people with ALS and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer v2. Repeat motif configurations of Australian ALS cases and healthy controls were manually derived from REViewer images. Receiver operating characteristic (ROC) curve analysis and Youden’s J statistic were performed to find a candidate repeat size threshold for association testing. Fisher’s exact tests were performed to evaluate the associations of repeat size and motif composition with disease status. Results: Analysis of 5,785 people with ALS and 7,982 healthy controls found no association between ZFHX3 GGC repeat expansions and disease risk. Fifty unique repeat motif compositions were identified across 802 people with ALS and 800 healthy controls. Of these, eleven distinct configurations coded a pure polyglycine tract which, when expanded, is canonical to SCA4, though no association with ALS was found. Discussion: Although no association was observed between ZFHX3 GGC repeat expansions and ALS, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Unique motif compositions were identified both within and between repeat sizes, including the presence of pure polyglycine repeats. Consideration of repeat motif composition and configuration, in addition to repeat allele length, may be important for assessing neurodegenerative disease risk.

  • Open Access

    Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia

    by Lyndal Henden, Liam G. Fearnley, Natalie Grima, Emily P. McCann, Carol Dobson-Stone, Lauren Fitzpatrick, Kathryn Friend, Lynne Hobson, Sandrine Chan Moi Fat, Dominic B. Rowe, et al.

    Pathogenic short tandem repeat (STR) expansions cause over 20 neurodegenerative diseases. To determine the contribution of STRs in sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), we used ExpansionHunter, REviewer, and polymerase chain reaction validation to assess 21 neurodegenerative disease-associated STRs in whole-genome sequencing data from 608 patients with sporadic ALS, 68 patients with sporadic FTD, and 4703 matched controls. We also propose a data-derived outlier detection method for defining allele thresholds in rare STRs. Excluding C9orf72 repeat expansions, 17.6% of clinically diagnosed ALS and FTD cases had at least one expanded STR allele reported to be pathogenic or intermediate for another neurodegenerative disease. We identified and validated 162 disease-relevant STR expansions in C9orf72 (ALS/FTD), ATXN1 [spinal cerebellar ataxia type 1 (SCA1)], ATXN2 (SCA2), ATXN8 (SCA8), TBP (SCA17), HTT (Huntington’s disease), DMPK [myotonic dystrophy type 1 (DM1)], CNBP (DM2), and FMR1 (fragile-X disorders). Our findings suggest clinical and pathological pleiotropy of neurodegenerative disease genes and highlight their importance in ALS and FTD.


  • Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis

    by Emily P McCann, Lyndal Henden, Jennifer A Fifita, Katharine Y Zhang, Natalie Grima, Denis C Bauer, Sandrine Chan Moi Fat, Natalie A Twine, Roger Pamphlett, Matthew C Kiernan, et al.

    Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with phenotypic and genetic heterogeneity. Approximately 10% of cases are familial, while remaining cases are classified as sporadic. To date, >30 genes and several hundred genetic variants have been implicated in ALS. Methods: Seven hundred and fifty-seven sporadic ALS cases were recruited from Australian neurology clinics. Detailed clinical data and whole genome sequencing (WGS) data were available from 567 and 616 cases, respectively, of which 426 cases had both datasets available. As part of a comprehensive genetic analysis, 853 genetic variants previously reported as ALS-linked mutations or disease-associated alleles were interrogated in sporadic ALS WGS data. Statistical analyses were performed to identify correlation between clinical variables, and between phenotype and the number of ALS-implicated variants carried by an individual. Relatedness between individuals carrying identical variants was assessed using identity-by-descent analysis. Results: Forty-three ALS-implicated variants from 18 genes, including C9orf72, ATXN2, TARDBP, SOD1, SQSTM1 and SETX, were identified in Australian sporadic ALS cases. One-third of cases carried at least one variant and 6.82% carried two or more variants, implicating a potential oligogenic or polygenic basis of ALS. Relatedness was detected between two sporadic ALS cases carrying a SOD1 p.I114T mutation, and among three cases carrying a SQSTM1 p.K238E mutation. Oligogenic/polygenic sporadic ALS cases showed earlier age of onset than those with no reported variant. Conclusion: We confirm phenotypic associations among ALS cases, and highlight the contribution of genetic variation to all forms of ALS.


  • Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice

    by Emily P McCann, Jennifer A Fifita, Natalie Grima, Jasmin Galper, Prachi Mehta, Sarah E Freckleton, Katharine Y Zhang, Lyndal Henden, Alison L Hogan, Sandrine Chan Moi Fat, et al.

    Objective: Since the first report ofCHCHD10gene mutations in amyotrophiclateral sclerosis (ALS)/frontotemporaldementia (FTD) patients, genetic variation inCHCHD10has been inconsistently linked to disease. A pathological assessment of the CHCHD10 protein in patient neuronal tissue also remains to be reported. We sought to characterise the genetic and pathological contribution of CHCHD10 to ALS/FTD in Australia.Methods: Whole-exome and whole-genome sequencing data from 81 familial and 635 sporadic ALS, and 108 sporadic FTD cases, were assessed for genetic variation inCHCHD10. CHCHD10 protein expression was characterised by immunohistochemistry, immunofluorescence and western blotting in control, ALS and/or FTD postmortem tissues and further in a transgenic mouse model of TAR DNA-binding protein 43 (TDP-43) pathology.Results: No causal, novel or disease-associated variants inCHCHD10were identified in Australian ALS and/or FTD patients. In human brain and spinal cord tissues, CHCHD10 was specifically expressed in neurons. A significant decrease in CHCHD10 protein level was observed in ALS patient spinal cord and FTD patient frontal cortex. In a TDP-43 mouse model with a regulatable nuclear localisation signal (rNLS TDP-43 mouse), CHCHD10 protein levels were unaltered at disease onset and early in disease, but were significantly decreased in cortex in mid-stage disease.Conclusions: Genetic variation inCHCHD10is not a common cause of ALS/FTD in Australia. However, we showed that in humans, CHCHD10 may play a neuron-specific role and a loss of CHCHD10 function may be linked to ALS and/or FTD. Our data from the rNLS TDP-43 transgenic mice suggest that a decrease in CHCHD10 levels is a late event in aberrant TDP-43-induced ALS/FTD pathogenesis.